Pioneering the Use of Novel E3 Ligases for Precision Protein Degradation

• Current therapies target only 400 out of over 4,000 disease-associated proteins, emphasizing the necessity for expanded E3 ligase applications.
• Curated an extensive list of E3 ligases, analyzing their ligandability, expression patterns, and interactions using advanced tools like UbiHub, UbiBrowser, and E3Atlas.
• Evaluated E3 ligase expression across various cancer types to identify optimal candidates for safe and effective cancer therapy.
• Identified C10orf90 as a potential superior TP53-specific E3 ligase, marking a significant advancement in targeted protein degradation strategies.